UNSPSC 51143903: Deanol

This classification denotes an antidepressant agent with the molecular formula C4H11NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2N6K9DRA24, chemically known as 2-(n,n-dimethylamino)ethanol but more generally known as deanol, which bears US NIH Compound Identifier 7902. European Medicines Agency schedules Deanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13534MIG. World Health Organization schedules deanol in its Anatomical Therapeutic Chemical (ATC) Classification.

DEANOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DEANOL remains US FDA's Preferred Term for this commodity. Deanol bears US NLM identifiers UMLS ID C0011064 and NCI Concept Code C72733. SMILES: OCCN(C)C.

UNSPSC 51143903 Deanol is a Commodity code that describes pharmaceutical and health-care products, but the recent state and local opportunities tagged under it reflect a broader procurement pattern: naloxone and drug deactivation systems for community health and harm-reduction initiatives, generic pharmaceuticals and over-the-counter (OTC) products through cooperative purchasing alliances, and direct-to-manufacturer prescription program capabilities. State and local issuing bodies under this code include county health departments, state HHS agencies, and multistate cooperative purchasing organizations that source on behalf of multiple jurisdictions and member agencies. Scope spans supply contracts for emergency medical countermeasures (naloxone kits), bulk generic pharmaceutical procurement with specific manufacturing and supply-chain compliance requirements, and exploratory market-intelligence gathering around alternative pharmacy benefit delivery models.

Recent activity includes Seminole County, Florida issuing an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issuing an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state, local, and interstate facilities including Oregon, with wholesaler distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson; and the Texas Health and Human Services Commission issuing an RFI on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs for self-insured employer and state agency plans. The three opportunities span Florida, Minnesota–Oregon, and Texas, with activity concentrated in cooperative purchasing vehicles and state health benefit administration. MMCAP's RFP emphasizes price competitiveness (75 percent of evaluation weight), compliance with current Good Manufacturing Practices and Drug Supply Chain Security Act certification, and pricing flexibility across flat, net, and WAC-minus structures; no explicit set-aside designations are identified across the recent solicitations.